Biophta aims to radically improve the efficacy of eye treatments by leveraging the first 7-day continuous microdosing pharmaceutical form
Biophta aims to radically improve the efficacy of eye treatments by leveraging the first 7-day continuous microdosing pharmaceutical form. Patients self-administer dry mini-tablets that turn into a gel and adhere to the eye surface, providing controlled, low-dose drug release.